脊髓灰质炎终局的抗病毒开发:目前的进展和未来的方向
Hang Xie1, Eric E Rhoden1, Hong-Mei Liu1
1Poliovirus & Picornavirus Branch, Division of Viral Diseases, National Center for Immunization and Other Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Pathogens (Basel, Switzerland)
|November 27, 2024
概括
开发抗病毒药物对于保持无脊髓灰质炎世界至关重要. 脊髓灰质炎抗病毒药物倡议 (PAI) 专注于抗病毒药物,以预防免疫受损个体的疫苗衍生的脊髓灰质炎病毒.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 药物发现 药物发现 药物发现
背景情况:
- 全球努力正在接近野生脊髓灰质炎病毒血清型1的根除.
- 口服脊髓灰质炎疫苗 (OPV) 携带疫苗相关麻性脊髓灰质炎 (VAPP) 的风险.
- 与免疫缺陷相关的疫苗衍生的脊髓灰质炎病毒 (iVDPV) 在B细胞缺乏个体中构成威胁.
研究的目的:
- 审查开发安全有效的小儿麻病毒抗病毒药物的进展情况.
- 为突出治疗IVDPV感染的有希望的抗病毒候选人.
- 为了支持一个持续无脊髓灰质炎世界的目标.
主要方法:
- 关于小儿麻病毒抗病毒研究的文献综述.
- 在体外,体内和临床试验数据的总结.
- 对针对脊髓灰质炎病毒复制的候选药物的分析.
主要成果:
- 在发现小儿麻病毒抗病毒药物方面取得了重大进展.
- 确定了几个有前途的抗病毒候选者.
- 在临床前和临床研究中证明了某些抗病毒药物的有效性.
结论:
- 开发抗病毒药物对于根除脊髓灰质炎病毒和预防VAPP至关重要.
- 脊髓灰质炎抗病毒药物倡议 (PAI) 是解决IVDPV风险的关键.
- 需要继续进行研究和临床试验,才能使有效的脊髓灰质炎抗病毒药物取得成果.
相关概念视频
Viruses with RNA Genomes
3
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
3
Microorganisms in Medicine and Therapeutics
1
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1


